Back

Notification report


Full notification file


General information

Notification Number
B/DE/15/PEI2482

Member State to which the notification was sent
Germany

Date of acknowledgement from the Member State Competent Authority
24/07/2015

Title of the Project
A phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Proposed period of release:
02/11/2015 to 31/08/2021

Name of the Institute(s) or Company(ies)
Novartis Pharma AG, Postfach, 4002 Basel, Switzerland;


3. Is the same GMO release planned elsewhere in the Community?
Yes:


Has the same GMO been notified elsewhere by the same notifier?
Yes

If yes, notification number(s):


GMO characterization

GMO is a:
Other: mammal

Identity of the GMO:


Information relating to the recipient or parental organisms from wich the GMO is derived
Common NameGenusSpeciesSubspeciesStrainPathovar
HumanHomo----

European Commission administrative information

Consent given by the Member State Competent Authority:
Yes
21/01/2016 00:00:00
Remarks: